Iron carbohydrate complex for treatment of restless leg syndrome (rls)
AssigneePharmacosmos Holding A/S
InventorsLars Lykke THOMSEN, Tobias S. CHRISTENSEN, Hans ANDREASEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
Claims21
-40. (canceled)
A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
- (a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum;
- and
- (b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
- wherein the iron carbohydrate complex comprises an iron reduced glucooligosaccharide;
- and
- wherein the weight average molecular weight (MW) of the carbohydrate component of the iron carbohydrate complex is 800 to 2,000 Dalton.
A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
- (a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum;
- and
- (b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
- wherein the iron carbohydrate complex is iron isomaltoside 1000.
A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
- (a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum;
- and
- (b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
- wherein the iron carbohydrate complex is iron isomaltoside 1000;
- wherein the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 800 mg elemental iron or more, or is 1,000 mg elemental iron;
- and
- wherein the pharmaceutical composition is infused into the patient during a 3 to 30 minute time period.
Dependencies are inferred from the claim text.